Abstract
Background: Salviae miltiorrhizae and ligustrazine hydrochloride injection (SMLHI), a kind of Chinese herbal medicine injection, has been considered as a promising supplementary treatment for acute ischemic stroke (AIS). However, its clinical efficacy is still not well investigated. In this study, the randomized controlled trials (RCTs) of SMLHI for the treatment of AIS were systematically reviewed to evaluate its clinical efficacy and safety.
Methods and analysis: All available randomized controlled trials (RCTs) that investigated the efficacy and safety ofSMLHI for patients with AIS were searched from the following electronic databases: Google Scholar, PubMed, Cochrane Library, Medline, Embase, Web of Science (WOS), Chinese Biomedical Literature Database (CBLD), China National Knowledge Infrastructure (CNKI), China Scientific Journal Database (CSJ) and Wanfang Database. Papers in Chinese or English published from their inception to December 2023 will be included without any restrictions.
Study selection and data extraction will be performed independently by 2 investigators. The clinical outcomes including neurological deficit score (NIHSS), activity of daily living (ADL), hemorheology and blood lipid indexes were systematically evaluated. Stata 14.0 and Review Manager 5.3 were used for data synthesis, sensitivity analysis, meta regression, subgroup analysis, and risk of bias assessment.
Discussion: The findings of this analysis will provide a helpful evidence for clinicians to formulate the best postoperative adjuvant treatment strategy for patients with AIS, and also provide scientific clues for researchers in this field.
Trial registration number: INPLASY202450033